HK1244004A1 - 内酰胺激酶抑制劑 - Google Patents

内酰胺激酶抑制劑

Info

Publication number
HK1244004A1
HK1244004A1 HK18103455.2A HK18103455A HK1244004A1 HK 1244004 A1 HK1244004 A1 HK 1244004A1 HK 18103455 A HK18103455 A HK 18103455A HK 1244004 A1 HK1244004 A1 HK 1244004A1
Authority
HK
Hong Kong
Prior art keywords
kinase inhibitors
lactam kinase
lactam
inhibitors
kinase
Prior art date
Application number
HK18103455.2A
Other languages
English (en)
Inventor
Francis Xavier Tavares
Original Assignee
Francis Xavier Tavares
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Francis Xavier Tavares filed Critical Francis Xavier Tavares
Publication of HK1244004A1 publication Critical patent/HK1244004A1/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/20Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK18103455.2A 2012-03-29 2018-03-12 内酰胺激酶抑制劑 HK1244004A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261617657P 2012-03-29 2012-03-29

Publications (1)

Publication Number Publication Date
HK1244004A1 true HK1244004A1 (zh) 2018-07-27

Family

ID=49261191

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18103455.2A HK1244004A1 (zh) 2012-03-29 2018-03-12 内酰胺激酶抑制劑

Country Status (6)

Country Link
US (4) US9260442B2 (zh)
EP (2) EP2831080B1 (zh)
AU (1) AU2013239816B2 (zh)
CA (1) CA2868966C (zh)
HK (1) HK1244004A1 (zh)
WO (1) WO2013148748A1 (zh)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8691830B2 (en) 2010-10-25 2014-04-08 G1 Therapeutics, Inc. CDK inhibitors
KR101929593B1 (ko) * 2010-10-25 2018-12-14 쥐원 쎄라퓨틱스, 인크. Cdk 억제제
AU2013239816B2 (en) 2012-03-29 2017-08-24 G1 Therapeutics, Inc. Lactam kinase inhibitors
CN104302620A (zh) 2012-04-26 2015-01-21 弗朗西斯·泽维尔·塔瓦雷斯 内酰胺的合成
ME03557B (me) 2013-03-15 2020-07-20 G1 Therapeutics Inc Privremena zaštiтa normalnih ćelija током hemoterapije
JP6435315B2 (ja) 2013-03-15 2018-12-05 ジー1、セラピューティクス、インコーポレイテッドG1 Therapeutics, Inc. 高活性抗新生物薬及び抗増殖剤
US9717735B2 (en) 2014-04-17 2017-08-01 G1 Therapeutics, Inc. Tricyclic lactams for use in HSPC-sparing treatments for RB-positive abnormal cellular proliferation
TWI713455B (zh) 2014-06-25 2020-12-21 美商伊凡克特治療公司 MnK抑制劑及其相關方法
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
EP3191098A4 (en) 2014-09-12 2018-04-25 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
WO2016203347A1 (en) * 2015-06-17 2016-12-22 Pfizer Inc. Tricyclic compounds and their use as phosphodiesterase inhibitors
US10112955B2 (en) 2015-10-29 2018-10-30 Effector Therapeutics, Inc. Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of Mnk1 and Mnk2
JP6888006B2 (ja) 2015-10-29 2021-06-16 イーフェクター セラピューティクス, インコーポレイテッド Mnk1およびmnk2を阻害するピロロ−、ピラゾロ−、イミダゾ−ピリミジンおよびピリジン化合物
US10000487B2 (en) 2015-11-20 2018-06-19 Effector Therapeutics, Inc. Heterocyclic compounds that inhibit the kinase activity of Mnk useful for treating various cancers
WO2018005863A1 (en) * 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based compounds for the treatment of cancer
MX2019000200A (es) 2016-07-01 2019-09-26 G1 Therapeutics Inc Agentes antiproliferativos basados en pirimidina.
BR112018077155A2 (pt) 2016-07-01 2019-04-02 G1 Therapeutics, Inc. processo para preparar um composto, e, composto
WO2018005533A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Antiproliferative pyrimidine-based compounds
US11865176B2 (en) 2016-11-08 2024-01-09 Dana-Farber Cancer Institute, Inc. Compositions and methods of modulating anti-tumor immunity
KR20190092478A (ko) 2016-12-05 2019-08-07 쥐원 쎄라퓨틱스, 인크. 화학요법 레지멘 동안의 면역 반응의 보존
BR112019013814A2 (pt) 2017-01-06 2020-01-21 G1 Therapeutics Inc método para tratamento de câncer ou de um tumor em um indivíduo, composição farmacêutica, combinação, e, kit.
US11395821B2 (en) 2017-01-30 2022-07-26 G1 Therapeutics, Inc. Treatment of EGFR-driven cancer with fewer side effects
JP2020507588A (ja) 2017-02-14 2020-03-12 イーフェクター セラピューティクス, インコーポレイテッド ピぺリジン置換MnK阻害剤およびそれに関連する方法
US10578179B2 (en) * 2017-04-26 2020-03-03 Fox Factory, Inc. Multi-mode air shock
KR102659211B1 (ko) 2017-06-29 2024-04-18 쥐원 쎄라퓨틱스, 인크. G1t38의 형체 형태 및 그의 제조 방법
JP2021509680A (ja) 2018-01-08 2021-04-01 ジー1、セラピューティクス、インコーポレイテッドG1 Therapeutics, Inc. G1t38の優れた投与レジメン
CN112839657A (zh) 2018-08-24 2021-05-25 G1治疗公司 1,4-二氮杂螺[5.5]十一烷-3-酮改进的合成
JP2022505846A (ja) 2018-10-24 2022-01-14 イーフェクター セラピューティクス, インコーポレイテッド Mnk阻害剤の結晶形態
WO2020206034A1 (en) * 2019-04-01 2020-10-08 G1 Therapeutics, Inc. Cell cycle inhibiting compounds for the treatment of medical disorders
JP2021167301A (ja) 2020-04-08 2021-10-21 ファイザー・インク Cdk2阻害剤に対する腫瘍適応を抑制するためのcdk4/6およびcdk2阻害剤による同時処置
AU2021273744A1 (en) 2020-05-19 2022-12-08 G1 Therapeutics, Inc. Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
TW202320795A (zh) 2021-07-26 2023-06-01 美商凱爾科迪股份有限公司 使用1-(4-{[4-(二甲胺基)哌啶-1-基]羰基}苯基)-3-[4-(4,6-二嗎啉-4-基-1,3,5-三-2-基)苯基]脲治療癌症之方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE391719T1 (de) 1997-02-05 2008-04-15 Warner Lambert Co Pyrido (2,3-d) pyrimidine und 4-amino-primidine als inhibitoren der zellulären proliferation
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
MXPA03000068A (es) * 2000-06-26 2003-09-25 Pfizer Prod Inc Compuestos de pirrolo (2,3-d)pirimidina como agentes inmunosupresores.
DK1470124T3 (da) 2002-01-22 2006-04-18 Warner Lambert Co 2-(Pyridin-2-yl amino)-pyrido[2,3]pyrimidin-7-oner
MXPA05007503A (es) 2003-01-17 2005-09-21 Warner Lambert Co Heterociclicos 2-aminopiridina sustituidos como inhibidores de proliferacion celular.
MXPA06000484A (es) 2003-07-11 2006-04-05 Warner Lambert Co Sal de isetionato de un inhibidor selectivo de la quinasa 4 dependiente de ciclina.
EP1678177B1 (en) 2003-10-23 2007-11-28 F.Hoffmann-La Roche Ag Triaza-spiropiperidine derivatives for use as glyt-1 inhibitors in the treatment of neurological and neuropsychiatric disorders
GB0327380D0 (en) 2003-11-25 2003-12-31 Cyclacel Ltd Method
ITMI20040874A1 (it) 2004-04-30 2004-07-30 Ist Naz Stud Cura Dei Tumori Derivati indolici ed azaindolici con azione antitumorale
ES2411975T3 (es) 2005-01-14 2013-07-09 Janssen Pharmaceutica Nv Pirimidinas heterocíclicas anilladas de 5 miembros como inhibidores de cinasas
CN101228161B (zh) * 2005-05-20 2012-10-10 沃泰克斯药物股份有限公司 适用作蛋白激酶抑制剂的吡咯并吡啶类
US20070049591A1 (en) * 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibitors of MAPK/Erk Kinase
EP1779848A1 (en) 2005-10-28 2007-05-02 Nikem Research S.R.L. V-ATPase inhibitors for the treatment of inflammatory and autoimmune diseases
ATE448230T1 (de) * 2005-12-09 2009-11-15 Hoffmann La Roche Für die behandlung von obesitas geeignete tricyclische amidderivate
MX2009013897A (es) 2007-06-25 2010-03-30 Neurogen Corp Piperacinil oxoalquil tetrahidro-beta-carbolinas y analogos relacionados.
WO2009085185A1 (en) * 2007-12-19 2009-07-09 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
CA2734802C (en) * 2008-08-22 2016-05-31 Novartis Ag Pyrrolopyrimidine compounds as cdk inhibitors
WO2010039997A2 (en) 2008-10-01 2010-04-08 The University Of North Carolina At Chapel Hill Hematopoietic protection against chemotherapeutic compounds using selective cyclin-dependent kinase 4/6 inhibitors
CN102231983A (zh) 2008-10-01 2011-11-02 北卡罗来纳大学查珀尔希尔分校 使用选择性细胞周期蛋白依赖性激酶4/6抑制剂对抗电离辐射的造血防护
JP2012526850A (ja) 2009-05-13 2012-11-01 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル サイクリン依存性キナーゼ阻害剤及びその用法
US9040519B2 (en) 2010-02-18 2015-05-26 Medivation Technologies, Inc. Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
KR101929593B1 (ko) * 2010-10-25 2018-12-14 쥐원 쎄라퓨틱스, 인크. Cdk 억제제
US8691830B2 (en) 2010-10-25 2014-04-08 G1 Therapeutics, Inc. CDK inhibitors
AU2013239816B2 (en) 2012-03-29 2017-08-24 G1 Therapeutics, Inc. Lactam kinase inhibitors
CN104302620A (zh) 2012-04-26 2015-01-21 弗朗西斯·泽维尔·塔瓦雷斯 内酰胺的合成
JP6435315B2 (ja) 2013-03-15 2018-12-05 ジー1、セラピューティクス、インコーポレイテッドG1 Therapeutics, Inc. 高活性抗新生物薬及び抗増殖剤
ME03557B (me) 2013-03-15 2020-07-20 G1 Therapeutics Inc Privremena zaštiтa normalnih ćelija током hemoterapije
US20140274896A1 (en) 2013-03-15 2014-09-18 G1 Therapeutics, Inc. Transient Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing Radiation
US20160257688A1 (en) 2013-10-24 2016-09-08 Francis Xavier Tavares Process for Synthesis of Lactams
WO2015166370A1 (en) 2014-04-28 2015-11-05 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands
US9787460B2 (en) 2015-07-16 2017-10-10 LGS Innovations LLC Self-interference channel estimation system and method

Also Published As

Publication number Publication date
US20160108054A1 (en) 2016-04-21
US9856268B2 (en) 2018-01-02
EP3216792B1 (en) 2020-05-27
WO2013148748A1 (en) 2013-10-03
AU2013239816A1 (en) 2014-10-30
EP2831080B1 (en) 2017-03-15
US10464940B2 (en) 2019-11-05
US20170057972A1 (en) 2017-03-02
US9745316B2 (en) 2017-08-29
EP2831080A1 (en) 2015-02-04
CA2868966C (en) 2021-01-26
CA2868966A1 (en) 2013-10-03
US20150018348A1 (en) 2015-01-15
US9260442B2 (en) 2016-02-16
AU2013239816B2 (en) 2017-08-24
EP3216792A1 (en) 2017-09-13
US20180127431A1 (en) 2018-05-10
EP2831080A4 (en) 2015-09-09

Similar Documents

Publication Publication Date Title
HK1244004A1 (zh) 内酰胺激酶抑制劑
HK1210775A1 (zh) 作為激酶抑制劑的咪唑並三嗪甲腈
HK1208442A1 (zh) 作為 激酶抑制劑的取代的吡咯並嘧啶基氨基-苯並噻唑酮
HK1215577A1 (zh) 蛋白激酶抑制劑
LT2903618T (lt) Rho kinazės inhibitoriai
HK1212683A1 (zh) 多個激酶途徑抑制劑
HK1222647A1 (zh) 激酶抑制劑
HUE048834T2 (hu) Kináz inhibitorok
EP2917210A4 (en) KINASE INHIBITORS
HK1209277A1 (zh) -三嗪- -甲酰胺激酶抑制劑
IL229028A0 (en) Kinase inhibitors
PL2634185T3 (pl) Inhibitory kinazy TYK2
HK1209726A1 (zh) 蛋白激酶抑制劑
HK1199873A1 (zh) 激酶抑制劑
HK1213252A1 (zh) 雙環二氫吡啶酮激酶抑制劑
HK1205506A1 (zh) 炔類化合物的蛋白激酶抑制劑
SG11201500973WA (en) Amino-quinolines as kinase inhibitors
HK1208460A1 (zh) 蛋白激酶抑制劑
HK1209422A1 (zh) 抑制劑
HK1213181A1 (zh) 雙環氧雜內酰胺激酶抑制劑
HK1209316A1 (zh) 取代的吡啶酰胺激酶抑制劑